Nuclidium is a clinical-stage radiopharmaceutical company that develops novel radionuclide PET tracers for precision diagnostics.
Nuclidium has raised $33.6M in total funding. The most recent round was Series B. The last funding was announced in May 2026.
Nuclidium's investors include Highlight Capital, NRW.BANK, Kurma Partners, European Innovation Council, Eurazeo.
Nuclidium is headquartered in Basel, Switzerland.
Nuclidium is a clinical-stage radiopharmaceutical company that develops novel radionuclide PET tracers for precision diagnostics.
Nuclidium is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Nuclidium — Funding & Investors." VCBacked, May 28, 2026, https://www.vcbacked.co/company/nuclidium. Accessed September 14, 2026.
VCBacked. (2026). Nuclidium — Funding & Investors. Retrieved September 14, 2026, from https://www.vcbacked.co/company/nuclidium
{{cite web |title=Nuclidium — Funding & Investors |url=https://www.vcbacked.co/company/nuclidium |website=VCBacked |access-date=September 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated